Instruction for use: Veprena

Active substance Calcitonin

ATX Code H05BA01 Calcitonin

Pharmacological groups

Calcium-phosphorus exchange regulator [67]

Calcium-phosphorus metabolism regulator [Correctors of bone and cartilage tissue metabolism]

Nosological classification (ICD-10)

G56.4 Causalgia

Causalgic syndrome, Syndrome of causalgia

M53.1 neck and shoulder syndrome

Acute shoulder-scapular periarthritis, Shoulder periarthritis, Of shoulder periarthritis, Shoulder periarthritis,frozen shoulder, Periarthritis in humeroscapular area, shoulder hand syndrome

M53.8 Other specified dorsopathies

Pleiraptocular periarthritis, Plechelopatochny syndrome

M75.0 Adhesive shoulder capsulitis

Acute shoulder-scapular periarthritis, Duplay's disease, Duplay Syndrome, Frozen shoulder, Shoulder-shoulder periarthritis, Periarteritis humeroscapular, Shoulder periarthritis, Pleiraptocular periarthritis, Capsule, Frozen shoulder

M81.9 Other specified osteoporosis

Osteoporosis due to androgen deficiency, Primary osteoporosis, Osteoporosis in men, Parathyroid osteoporosis, Primary osteoporosis, Post-traumatic osteoporosis, Loss of calcium in bones and teeth, Presennial osteoporosis, Systemic osteoporosis

M81.0 Postmenopausal osteoporosis

Menopause osteoporosis, Osteoporosis in menopause, Osteoporosis in menopause, Osteoporosis in postmenopausal women, Osteoporosis in the postmenopausal period, Postmenopausal osteoporosis, Osteoporosis in postmenopausal women, Perimenopausal osteoporosis, Postmenopausal osteoporosis, Post-menopausal osteoporosis, Postmenopausal osteoporosis, Postmenopausal demineralization of bones, Osteoporosis with estrogen deficiency, Osteoporosis in postmenopausal women, Osteoporosis in postmenopausal women and after hysterectomy

M88 Paget's disease (bones) [deforming osteitis]

Paget's disease is bone, Paget's disease, Deforming osteodystrophy, Paget's disease, Deforming osteitis, Deforming Osteoporosis, Ostoz deforming, Osteitis deforming, Osteitis with articular manifestations

M89.0 Algoneurodroystrophy

Zudeck's atrophy, Zudeck's Syndrome, Shoulder-Arm Syndrome, Steinbroke Syndrome, Shoulder-Brush Syndrome, Brachialgia syndrome, Zudeck's posttraumatic reflex atrophy, Reflex sympathetic dystrophy

M89.5 Osteolysis

Acrosteolysis, Piknodizostoz, Osteolytic damage to bones, Spontaneous resorption of bones

M89.8 Other specified disorders of bones

Pain in the bones, Painful conditions of the musculoskeletal system

M89.9 Disease of bone, unspecified

Local osteopathy, Disturbance of bone mineralization processes, Osteopenia, Pain syndrome in acute inflammatory diseases of the musculoskeletal system, Pain syndrome in chronic inflammatory diseases of the musculoskeletal system, Pain in the musculoskeletal system, Infection of bones, Ossalgia, Pain in chronic degenerative bone diseases

M90.8 Osteopathy in other diseases classified elsewhere

Osteopathy, Local Osteopathy, Osteopenia, Nephrogenic osteopathy

Composition

Spray nasal dosed 1 dose

active substance:

Calcitonin 200 ME

Excipients: benzalkonium chloride - 9 mcg; Sodium chloride - 81 mcg; Hydrochloric acid concentrated to pH (3.7 ± 0.1); Water for injection - up to 90 μl

pharmachologic effect

Pharmacological action - regulating calcium-phosphorus metabolism, calcitonin, anti-osteoporosis.

Dosing and Administration

Intranasally, into one of the nasal passages.

For the treatment of osteoporosis: the recommended dose is 200 IU / day.

In order to prevent progressive loss of bone mass, concomitantly with the use of nasal spray, the administration of adequate doses of calcium and vitamin D is recommended. Treatment should be carried out for a long time.

For pains in the bones associated with osteolysis and / or osteopenia: the daily dose of the drug is 200-400 IU daily. A daily dose of 200 IU can be administered at a time. Higher doses should be divided into several injections. The dose should be adjusted to the individual needs of the patient. To achieve a complete analgesic effect may take several days. In long-term therapy, the initial daily dose is usually reduced and / or the interval between administrations is increased.

Duration of treatment is at least 3 months, if necessary, it can be more. The daily dose should be adjusted to the individual needs of the patient.

Paget's disease: the daily dose of the drug is 200 IU. In some cases, at the beginning of treatment, a dose of 400 IU / day may be required, given in several administrations.

With Paget's disease the duration of treatment should be from several months to several years. Against the backdrop of treatment, there is a significant decrease in the concentration of AP in the blood and excretion of hydroxyproline in the urine, sometimes to normal values. In some cases, after the initial decrease in the values of these indicators, it is possible to increase them. In these cases, the doctor, guided by the clinical picture, must decide whether treatment should be revoked and when it can be resumed. One or several months after discontinuation of treatment, bone metabolism disorders may occur again; In this case a new course will be required.

Neurodystrophic diseases: in a daily dose of 200 IU, daily for 2-4 weeks. An additional prescription for 200 IU every other day for 6 weeks is possible, depending on the dynamics of the patient's condition.

Use in elderly patients and selected patient groups

According to known data, elderly patients and patients with a decrease in kidney or liver function do not need to change the dosage regimen of the drug.

Application rules

1. Never shake the bottle; This can lead to the formation of air bubbles inside the vial, which will result in improper dosing of the drug.

2. Remove the protective cap. Hold the device with one or two hands strictly vertically, push the piston 3 times, which will allow air to exit the tube. Possible spattering of the solution is provided and does not affect the subsequent number of doses.

3. Remove the protective cap. Slightly tilt the head forward and insert the tip into the nasal passage. Make sure that the tip is aligned with the nasal passage, which will ensure a more even distribution of the solution. Press the plunger once. Remove the tip from the nose and take a few vigorous breaths to prevent the drug from escaping. Do not clean the nose immediately after applying the drug. If the doctor has appointed 2 injections for 1 reception, then the second injection should be done in the other nasal passage.

After use, the tip should be gently wiped with a clean dry cloth and put on the protective cap on the tip.

Form of issue

Spray nasal dosed, 200 IU / dose. 2 ml (14 doses) of the drug in vials of colorless glass with a screw-on dispensing dispenser. For 1 or 2 fl. In a cardboard box.

Terms of leave from pharmacies

On prescription.

Storage conditions

In the dark place at a temperature of 2-8 ° C.

Keep out of the reach of children.

Shelf life

2 years.

Do not use after the expiry date printed on the package.